埃索美拉唑在国内上市了吗？

Has it been launched in China? In late June 2014, the national Class 4 new drug esomeprazole enteric-coated capsules (Laimeisu) independently developed by Laimei Pharmaceutical was officially launched on the market, which means that the 15-year research and development of esomeprazole new drug, which started in 1999, was declared successful. It is understood that this new drug is expected to become Laimei Pharmaceutical's largest single product sales revenue in the next few years, with annual sales expected to reach $1 billion, becoming the company's largest profit contributor. With the sales of esomeprazole and the immunomodulator urticulin, which will be launched in the second half of the year, the company's exclusive new drug varieties will account for more than half of the sales.

Esomeprazole is a new generation of proton pump inhibitor (PPI), mainly suitable for the treatment of peptic ulcer. Compared with other proton pump inhibitors, esomeprazole has the advantages of shorter course of treatment, more stable efficacy, faster and longer onset of action, and higher HP ulcer eradication rate. It is the latest generation of drugs currently used to treat peptic ulcers.

The safety and effectiveness of esomeprazole treatment have been verified in two trials: a clinical comparative study of esomeprazole and omeprazole in the treatment of reflux esophagitis. The total effective rate of esomeprazole was 97.18%, which was significantly higher than that of omeprazole, which was 84.51%. There was no significant difference in the incidence of adverse reactions. Chen Caiming conducted a cost-effectiveness analysis of omeprazole and esomeprazole in the treatment of duodenal ulcer. The recovery rate of the esomeprazole group was 92.6%, which was higher than that of omeprazole, 78.6%. The results proved that esomeprazole has cost and effectiveness advantages. 

Esomeprazole maintains gastric pH >4 for a longer period of time. A study on the duration of gastric pH > 4 and the healing rate of reflux esophagitis showed that the longer the duration of pH > 4 within 24 hours, the greater the number of patients who healed after 8 weeks. After taking different drugs orally for 5 days, the duration of pH>4 in the stomach within 24 hours from longest to shortest is: esomeprazole 40 mg, omeprazole 40 mg, lansoprazole 30 mg, pantoprazole 40 mg and rabeprazole 20 mg. This shows that esomeprazole 40mg has a stronger acid-suppressing effect than other proton pump inhibitors. Clinical trials have also fully confirmed the excellent pH control ability of esomeprazole 40mg. Generally speaking, it is very effective in treating early-stage gastric cancer.